Vanguard Group’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-405,196
| Closed | -$3.52M | – | 4196 |
|
|
2018
Q2 | $3.52M | Buy |
405,196
+13,294
| +3% | +$120K | ﹤0.01% | 3330 |
|
|
2018
Q1 | $3.98M | Buy |
391,902
+28,439
| +8% | +$239K | ﹤0.01% | 3236 |
|
|
2017
Q4 | $1.76M | Buy |
363,463
+4,540
| +1% | +$22.1K | ﹤0.01% | 3462 |
|
|
2017
Q3 | $1.63M | Sell |
358,923
-18,578
| -5% | -$87.2K | ﹤0.01% | 3460 |
|
|
2017
Q2 | $1.91M | Sell |
377,501
-73,837
| -16% | -$330K | ﹤0.01% | 3394 |
|
|
2017
Q1 | $2.14M | Buy |
451,338
+1,942
| +0.4% | +$9.81K | ﹤0.01% | 3361 |
|
|
2016
Q4 | $2.52M | Buy |
449,396
+200
| +0% | +$1.1K | ﹤0.01% | 3286 |
|
|
2016
Q3 | $2.49M | Buy |
449,196
+13,569
| +3% | +$89.7K | ﹤0.01% | 3307 |
|
|
2016
Q2 | $3.05M | Buy |
435,627
+2,588
| +0.6% | +$18.2K | ﹤0.01% | 3206 |
|
|
2016
Q1 | $2.86M | Buy |
433,039
+55,137
| +15% | +$406K | ﹤0.01% | 3229 |
|
|
2015
Q4 | $3.89M | Buy |
377,902
+18,292
| +5% | +$212K | ﹤0.01% | 3100 |
|
|
2015
Q3 | $4.24M | Buy |
359,610
+51,715
| +17% | +$572K | ﹤0.01% | 3046 |
|
|
2015
Q2 | $2.82M | Buy |
307,895
+3,333
| +1% | +$25.2K | ﹤0.01% | 3276 |
|
|
2015
Q1 | $1.89M | Buy |
304,562
+23,890
| +9% | +$148K | ﹤0.01% | 3437 |
|
|
2014
Q4 | $1.57M | Buy |
280,672
+13,512
| +5% | +$78.7K | ﹤0.01% | 3369 |
|
|
2014
Q3 | $1.57M | Buy |
267,160
+12,712
| +5% | +$77.5K | ﹤0.01% | 3361 |
|
|
2014
Q2 | $1.74M | Buy |
254,448
+1,300
| +0.5% | +$8.7K | ﹤0.01% | 3317 |
|
|
2014
Q1 | $1.83M | Buy |
253,148
+18,777
| +8% | +$130K | ﹤0.01% | 3258 |
|
|
2013
Q4 | $1.55M | Sell |
234,371
-4,074
| -2% | -$27.7K | ﹤0.01% | 3298 |
|
|
2013
Q3 | $1.73M | Buy |
+238,445
| New | +$1.61M | ﹤0.01% | 3184 |
|
Vanguard Group's JNP Position: Q3 2018 in Review
Vanguard Group sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 405,196 shares — an estimated $3.52M sold.
Vanguard Group first reported a position in JNP in Q3 2013 and held it in 20 quarters. The position peaked at $4.24M in Q3 2015. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Vanguard Group reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Vanguard Group sold 405,196 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $3.52M.
- Vanguard Group first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 20 quarters.
- Vanguard Group's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $4.24M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Vanguard Group's 13F filing for Q3 2018, filed 14 Nov 2018.